BACKGROUND: Galectin-3 (gal-3) is an emerging prognostic biomarker in heart failure (HF). Clinical and experimental studies suggest that gal-3 is an important mediator of HF. Here we aimed to examine the relationship between gal-3 and diastolic dysfunction in patients undergoing maintenance hemodialysis (HD). METHODS: We examined the relationship between plasma gal-3 levels and left ventricular diastolic function. Plasma gal-3 was measured in 87 subjects with chronic HD and in 45 healthy controls using biochemical evaluations. Conventional echocardiography and pulsed tissue Doppler assessment were performed in all patients. Left ventricular diastolic dysfunction (LVDD) was defined as E' < 8 cm/s. The E/E' ratio was used as the main determinant of LVDD grade. RESULTS: The mean gal-3 concentrations were: 16.05 ng/ml (13.89-19.75) in healthy controls; 14.54 ng/ml (10.85-17.65) in HD patients with normal diastolic function; and 23.30 ng/ml (20.12-26.87) in HD patients with LVDD (p < 0.01). Plasma gal-3 levels correlated with E/E' (r = 0.933, p < 0.01), left atrial volume index (r = 0.713, p < 0.01), and E' (r = -0.685, p < 0.01). ROC analysis showed that the best gal-3 cut-off point for the diagnosis of LVDD was 20.12 ng/ml with a sensitivity of 67.6 % and specificity of 84.6 % (AUC = 0.803). CONCLUSION: We suggest that gal-3 may be a promising biomarker for the detection of LVDD in HD patients.
BACKGROUND:Galectin-3 (gal-3) is an emerging prognostic biomarker in heart failure (HF). Clinical and experimental studies suggest that gal-3 is an important mediator of HF. Here we aimed to examine the relationship between gal-3 and diastolic dysfunction in patients undergoing maintenance hemodialysis (HD). METHODS: We examined the relationship between plasma gal-3 levels and left ventricular diastolic function. Plasma gal-3 was measured in 87 subjects with chronic HD and in 45 healthy controls using biochemical evaluations. Conventional echocardiography and pulsed tissue Doppler assessment were performed in all patients. Left ventricular diastolic dysfunction (LVDD) was defined as E' < 8 cm/s. The E/E' ratio was used as the main determinant of LVDD grade. RESULTS: The mean gal-3 concentrations were: 16.05 ng/ml (13.89-19.75) in healthy controls; 14.54 ng/ml (10.85-17.65) in HDpatients with normal diastolic function; and 23.30 ng/ml (20.12-26.87) in HDpatients with LVDD (p < 0.01). Plasma gal-3 levels correlated with E/E' (r = 0.933, p < 0.01), left atrial volume index (r = 0.713, p < 0.01), and E' (r = -0.685, p < 0.01). ROC analysis showed that the best gal-3 cut-off point for the diagnosis of LVDD was 20.12 ng/ml with a sensitivity of 67.6 % and specificity of 84.6 % (AUC = 0.803). CONCLUSION: We suggest that gal-3 may be a promising biomarker for the detection of LVDD in HDpatients.
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Eur J Heart Fail Date: 2010-06-05 Impact factor: 15.534
Authors: H Yilmaz; O M Gurel; H T Celik; A Bozkurt; M E Yildirim; I Bilgic; M A Bilgic; N Bavbek; A Akcay Journal: Herz Date: 2014-06-14 Impact factor: 1.443
Authors: James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski Journal: Am J Cardiol Date: 2005-04-15 Impact factor: 2.778
Authors: Ali Ahmed; Michael W Rich; Paul W Sanders; Gilbert J Perry; George L Bakris; Michael R Zile; Thomas E Love; Inmaculada B Aban; Michael G Shlipak Journal: Am J Cardiol Date: 2006-12-08 Impact factor: 2.778
Authors: A Rogier van der Velde; Lars Gullestad; Thor Ueland; Pål Aukrust; Yu Guo; Aram Adourian; Pieter Muntendam; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Circ Heart Fail Date: 2013-02-08 Impact factor: 8.790
Authors: Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen Journal: Ann Med Date: 2010-12-28 Impact factor: 4.709
Authors: Uzair Ansari; Michael Behnes; Julia Hoffmann; Michele Natale; Christian Fastner; Ibrahim El-Battrawy; Jonas Rusnak; Seung Hyun Kim; Siegfried Lang; Ursula Hoffmann; Thomas Bertsch; Martin Borggrefe; Ibrahim Akin Journal: Ann Lab Med Date: 2018-07 Impact factor: 3.464
Authors: Eryk Latoch; Katarzyna Konończuk; Anna Jander; Elżbieta Trembecka-Dubel; Anna Wasilewska; Katarzyna Taranta-Janusz Journal: J Clin Med Date: 2021-05-08 Impact factor: 4.241